Pratley, Richard E.
Crowley, Matthew J.
Gislum, Mette
Hertz, Christin L.
Jensen, Thomas B.
Khunti, Kamlesh
Mosenzon, Ofri
Buse, John B.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
https://doi.org/10.1007/s41669-023-00416-z
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3
https://doi.org/10.2337/db19-111-lb
Documents that mention this clinical trial
55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4
https://doi.org/10.2337/db19-55-or
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy
https://doi.org/10.1136/bmjopen-2022-070473
927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
https://doi.org/10.2337/db20-927-p
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
Documents that mention this clinical trial
1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
https://doi.org/10.2337/db19-1004-p
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
https://doi.org/10.1186/s12933-022-01585-7
Documents that mention this clinical trial
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
https://doi.org/10.1136/bmjdrc-2020-001649
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7
https://doi.org/10.2337/db19-983-p
Documents that mention this clinical trial
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
https://doi.org/10.2337/dc19-0898
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin
https://doi.org/10.2337/db20-956-p
985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8
https://doi.org/10.2337/db19-985-p
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 17 November 2020
Accepted: 23 December 2020
First Online: 4 March 2021